Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 13/20 | 0.50 |
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817917 | 0.92 | NEK7 (0.51) | NEK7RET | |
| SCHEMBL24096542 | 0.90 | NEK7 (0.63) | NEK7RETKDRLCKSRC | |
| SCHEMBL25793475 | 0.88 | NEK7 (0.60) | NEK7RETKDRLCKSRC | |
| SCHEMBL25817932 | 0.87 | NEK7 (0.50) | NEK7RETKDRLCKSRC | |
| SCHEMBL25817986 | 0.85 | NEK7 (0.48) | NEK7RETKDRLCKSRC | |
| SCHEMBL25817977 | 0.85 | NEK7 (0.47) | NEK7RETKDRLCKSRC | |
| SCHEMBL25793532 | 0.85 | NEK7 (0.64) | NEK7RET | |
| SCHEMBL25817922 | 0.85 | NEK7 (0.47) | NEK7RETKDRLCKSRC | |
| SCHEMBL25793479 | 0.84 | NEK7 (0.61) | NEK7 | |
| SCHEMBL25793476 | 0.83 | NEK7 (0.48) | NEK7RETKDRLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | NEK7 1/4885RET 805/4885KDR 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.